Incyte (INCY) Financial Analysis & Valuation | Quarter Chart
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growt... more
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commerci... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $25.40B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William J. Meury |
| IPO Date | 1993-11-04 | CAGR | 35.62% |
| Employees | 2,844 | Website | www.incyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
INCY chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $18.86B | P/E | 16.84 | Forward P/E | 14.1 | PEG | 0.43 |
| P/S | 2.03 | P/B | 1.84 | P/CF | 5.99 | P/FCF | 6.13 |
| Sales | $5.82B | Sales 1Y | 26.93% | Sales 3Y | 65.64% | Sales 5Y | 113.91% |
| EPS | $7.44 | EPS 1Y | 78.41% | EPS 3Y | 382.72% | EPS 5Y | 416.28% |
| Sales QoQ | 31.54% | EPS QoQ | 91.16% | Sales QoQ Avg | 9.67% | EPS QoQ Avg | 16.12% |
| Gross Margin | 92.62% | Operating Margin | 31.57% | Profit Margin | 27.71% | ROCE | 28.01% |
| ROA | 20% | ROE | 30% | Altman Z Score | 12.72 | Piotroski Score | 6 |
| Current Ratio | 4.66 | Quick Ratio | 4.31 | Cash Ratio | 3.04 | Op. CF Ratio | 0.39 |
| Debt/Equity | 0.01 | Debt/Assets | 0 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | 0 |
| Intrst Cov. | 790.59 | Inventory Turnover | 0.94 | Asset Turnover | 0.74 | Receivables Turnover | 5.17 |
| Enterprise Value | $18.86B | P/E Ratio | 16.84 |
| Forward P/E | 14.1 | PEG Ratio | 0.43 |
| P/S Ratio | 2.03 | P/B Ratio | 1.84 |
| P/CF Ratio | 5.99 | P/FCF Ratio | 6.13 |
| EPS | $7.44 | EPS Growth 1Y | 78.41% |
| EPS Growth 3Y | 382.72% | EPS Growth 5Y | 416.28% |
| Revenue Growth 1Y | 26.93% | Gross Margin | 92.62% |
| Operating Margin | 31.57% | Profit Margin | 27.71% |
| ROE | 30% | ROA | 20% |
| ROCE | 28.01% | Current Ratio | 4.66 |
| Quick Ratio | 4.31 | Cash Ratio | 3.04 |
| Debt/Equity | 0.01 | Interest Coverage | 790.59 |
| Altman Z Score | 12.72 | Piotroski Score | 6 |
Incyte (INCY) valuation & financials
Incyte (INCY) has a market capitalization of $25.40B and trades at a price-to-earnings ratio of 16.8. It operates in the Healthcare sector (Biotechnology).
Incyte's revenue grew +26.9% over the last year.
Incyte's next earnings report is scheduled for October 27, 2026 before market open (provider scheduled date); analysts estimate EPS of $-3.31. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)